[DOI] [PMC free article] [PubMed] [Google Scholar] 174.Ferri A., Fiorenzo P., Nencini M., Cozzolino M., Pesaresi M.G., Valle C., Sepe S., Moreno S., Carr M.T
Nausea affects roughly 25% of users, particularly during the first 8 weeks of treatment
Hearty, filling, and full of fiber
Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management
Retatrutide Phase 3 Updates: Significant Weight Loss and Improved Complications Retatrutide Phase 3 (ADA 2026) Key Updates at a Glance By Eli Lilly and Company Retatrutide continues to position itself as one of the most potent obesity therapies in development, demonstrating substantial weight loss while simultaneously improving multiple obesity-related complications
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain